Compare · CPNG vs LOGC
CPNG vs LOGC
Side-by-side comparison of Coupang Inc. (CPNG) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CPNG and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
- CPNG is the larger of the two at $30.00B, about 615.1x LOGC ($48.8M).
- Over the past year, CPNG is down 41.9% and LOGC is up 0.0% - LOGC leads by 41.9 points.
- CPNG has been more active in the news (7 items in the past 4 weeks vs 6 for LOGC).
- CPNG has more recent analyst coverage (25 ratings vs 5 for LOGC).
- Company
- Coupang Inc.
- ContextLogic Inc.
- Price
- $16.52-0.96%
- $7.05+1.00%
- Market cap
- $30.00B
- $48.8M
- 1M return
- +7.10%
- +0.00%
- 1Y return
- -41.85%
- +0.00%
- Industry
- Catalog/Specialty Distribution
- Catalog/Specialty Distribution
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 5
Coupang Inc.
Coupang, Inc. owns and operates in e-commerce business through its mobile applications and Internet websites primarily in South Korea. It sells various products and services in the categories of home goods and décor products, apparel, beauty products, fresh food and groceries, sporting goods, electronics, and everyday consumables, as well as travel, and restaurant order and delivery services. The company was founded in 2010 and is based in Seoul, South Korea.
ContextLogic Inc.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest CPNG
- Officer Rogers Harold sold $3,107,975 worth of shares (192,110 units at $16.18), decreasing direct ownership by 21% to 740,931 units (SEC Form 4) (withholding obligation)
- Chief Accounting Officer Lee Jonathan D. sold $88,867 worth of shares (5,519 units at $16.10) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 181,915 units (SEC Form 4) to cover taxes
- Coupang upgraded by Deutsche Bank with a new price target
- SEC Form 10-Q filed by Coupang Inc.
- Coupang Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Coupang Announces Results for Second Quarter 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Coupang Inc.
- U.S. Tech Company Coupang Inc. Named to 2026 Fortune Global 500™ for the First Time, Bolstered by AI-Powered Global Commerce Investments
- Coupang to Announce Second Quarter 2026 Results on August 4, 2026
- CLSA initiated coverage on Coupang with a new price target
Latest LOGC
- ContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 Results
- SEC Form 10-Q filed by ContextLogic Inc.
- ContextLogic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial Results
- ContextLogic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- ContextLogic to Acquire gChem for $850 Million
- Amendment: ContextLogic Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- ContextLogic Appoints Seth Siegel as Senior Advisor
- ContextLogic Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CFO & COO Stewart Scott Matthew bought $97,600 worth of shares (10,000 units at $9.76), increasing direct ownership by 20% to 60,000 units (SEC Form 4)